This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Immune Checkpoint Inhibitors: A Pathway to Identifying and Managing Unique Adverse Events in Cancer Care

Immune Checkpoint Inhibitors: A Pathway to Identifying and Managing Unique Adverse Events in Cancer Care

Format

Webcast

Time to Complete

1.25 hours

Released

December 21, 2018

Expires

December 20, 2019
Add to Queue


Maximum Credits

1.25 / AMA PRA Category 1 CreditsTM
1.25 / CNE Contact Hours

Accredited Provider

This activity is provided by Haymarket Medical Education for physician credit.

This activity is jointly provided by Global Education Group and Haymarket Medical Education for nursing contact hours.

Commercial Supporter

Supported by an educational grant from AstraZeneca

Program Description

The last few years have seen the emergence of several immuno-oncology agents for treating patients with advanced cancer, including checkpoint inhibitors such as the cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4) inhibitor ipilimumab, programmed cell death protein 1 (PD-1) checkpoint inhibitors nivolumab and pembrolizumab, and programmed death-ligand 1 (PD-L1) checkpoint inhibitors atezolizumab, avelumab, and durvalumab. These agents, which target cell-surface checkpoint proteins, have demonstrated efficacy for a multitude of solid tumors and hematologic malignancies, such as melanoma, non–small-cell lung carcinoma, advanced renal cell carcinoma, metastatic head and neck squamous cell carcinoma, bladder cancer, Hodgkin lymphoma, metastatic Merkel cell carcinoma, and urothelial cancer. In light of the numbers of approved immune checkpoint inhibitors and many others in development, it is essential that oncologists, hematologists, oncology nurses, and others on the multidisciplinary team (endocrinologists, dermatologists, pulmonologists, gastroenterologists, etc) become more familiar with the mechanisms of action of PD-1, PD-L1, and CTLA-4 inhibitors, including differentiating them from traditional chemotherapy, and are able to identify, monitor, and manage the immune-related adverse events that can accompany the use of these immunotherapeutic agents.

Intended Audience

This activity is designed for oncologists, oncologists-hematologists, emergency medicine physicians, oncology nurses, nurse practitioners (NPs), physician assistants (PAs), and other providers who care for patients with cancer.

Educational Objectives

After completing the activity, the participant should be better able to:

  • Differentiate between the mechanisms of action and potential immune-related adverse events (irAEs) of checkpoint inhibitors and traditional chemotherapeutic agents
  • Institute guideline-recommended strategies to identify, monitor, and manage irAEs of checkpoint inhibitors
  • Develop a team-based network of clinicians and patients to effectively manage and mitigate irAEs

Conflict Of Interest Disclosure Policies

In accordance with the ACCME Standards for Commercial Support, HME and Global require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME and Global resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Furthermore, HME and Global Education Group (Global) seek to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. HME and Global are committed to providing their learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.

Faculty

MODERATOR
Peter Salgo, MD

Professor of Medicine and Anesthesiology
Columbia University College of Physicians and Surgeons
Associate Director, Surgical Intensive Care
Columbia University Medical Center
New York, NY

Dr. Salgo has no relevant financial relationships to disclose.

FACULTY PRESENTERS
Sanjiv S. Agarwala, MD

Chief, Medical Oncology & Hematology
St. Luke’s Cancer Center
Bethlehem, PA
Professor of Medicine
Temple University School of Medicine
Philadelphia, PA

Dr. Agarwala has no relevant financial relationships to disclose.

Kelly J. Brassil, PhD, RN, AOCNS
Director, Nursing Programs
University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Brassil receives grant research support from Astellas and Genentech.

Everett E. Vokes, MD
John E. Ultmann Professor
Chairman, Department of Medicine
Physician-in-Chief, University of Chicago Medicine
Chicago, IL

Dr. Vokes receives consultant fees from AbbVie, Amgen, AstraZeneca, Biolumina, Bristol-Myers Squibb, Celgene, Eli Lilly, EMD Serono, Genentech, Merck, Novartis, and Regeneron.

RuthAnn Gordon, MSN, FNP-BC, RN, OCN
Memorial Sloan Kettering Cancer Center
Middletown, NJ

Ms. Gordon has no relevant financial relationships to disclose.

Accredited Provider Disclosure

Nick Zittell and Susan Basilico of Haymarket Medical Education involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Ashley Marostica, Andrea Funk, Liddy Knight, and Ashley Cann of Global Education Group involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

1.25

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.25

Type

CNE Contact Hour(s)

Accreditation Statement

Global Education Group (Global) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC’s) Commission on Accreditation.

Designation Statement

This educational activity for 1.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. This activity is jointly provided by Global Education Group and Haymarket Medical Education (HME) for ANCC credit.

Additional Credit Information

Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 Category 1 Credits for completing this activity.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

Faculty, speakers, presenters, authors, activity medical directors, and moderators are required to disclose to the learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA-approved) as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education, Global Education Group, or AstraZeneca. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the CME accreditation of this activity, please contact please contact HME at cmequestions@haymarketmedical.com.

For information about the nursing accreditation of this program, please contact cme@globaleducationgroup.com.

If you have any other questions relating to your certificate or other issues with the activity, please contact
myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue